Ascendis Pharma A/S
NASDAQAscendis Pharma reports Q1 2026 results today against a backdrop of strengthening short-side sentiment — but options traders are firmly in the bull camp. The standout signal heading into the print is the options market. The put/call ratio has drifted toward its 52-week low, hitting 0.32 on Monday before settling at 0.34 — near the least defensive reading of the past year. With…
Snapshot as of 7 May 2026
Ascendis Pharma reports Q1 2026 results today against a backdrop of strengthening short-side sentiment — but options traders are firmly in the bull camp. The standout signal heading into the print is the options…
Ascendis Pharma enters its Q1 2026 earnings call — scheduled for tomorrow, May 7 — with its ORTEX short score having nearly doubled over the past two weeks, setting up one of the more charged pre-earnings positioning…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ASND — free to start on ORTEX.
Sign up for free →Open ASND on ORTEX